Trade Legend Biotech Corporation - LEGN CFD

Add to favourite

32.79

1.15%

0.13

Low: 32.53

High: 33.34

Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data

Trading сonditions

Spread

0.13

Long position overnight fee

-0.023568%

Short position overnight fee

0.001346%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	33.17
Open	32.91
1-Year Change	-47.58%
Day's Range	32.53 - 33.34

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 3, 2025	32.79	0.20	0.61%	32.59	33.39	32.34
Apr 2, 2025	33.17	1.87	5.97%	31.30	33.46	31.08
Apr 1, 2025	31.47	-2.58	-7.58%	34.05	34.20	31.34
Mar 31, 2025	33.87	-0.15	-0.44%	34.02	34.29	32.79
Mar 28, 2025	34.99	-0.35	-0.99%	35.34	35.49	34.51
Mar 27, 2025	35.32	0.25	0.71%	35.07	36.11	34.74
Mar 26, 2025	34.62	-0.21	-0.60%	34.83	34.89	33.95
Mar 25, 2025	34.95	-1.18	-3.27%	36.13	36.13	34.45
Mar 24, 2025	36.28	-0.67	-1.81%	36.95	37.28	36.02
Mar 21, 2025	36.89	-0.01	-0.03%	36.90	37.25	35.95
Mar 20, 2025	37.68	0.18	0.48%	37.50	37.87	36.95
Mar 19, 2025	38.03	0.39	1.04%	37.64	38.10	37.18
Mar 18, 2025	37.83	-0.12	-0.32%	37.95	38.09	37.26
Mar 17, 2025	37.88	0.77	2.07%	37.11	38.42	37.11
Mar 14, 2025	37.14	-0.97	-2.55%	38.11	38.54	36.38
Mar 13, 2025	38.00	0.54	1.44%	37.46	38.57	36.68
Mar 12, 2025	38.19	0.48	1.27%	37.71	38.53	36.92
Mar 11, 2025	37.11	3.14	9.24%	33.97	37.17	33.72
Mar 10, 2025	33.91	-0.56	-1.62%	34.47	35.21	33.90
Mar 7, 2025	35.20	0.77	2.24%	34.43	35.35	33.87

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Legend Biotech Corporation

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.